Home » Stocks » ANIK

Anika Therapeutics, Inc. (ANIK)

Stock Price: $39.23 USD -0.60 (-1.51%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 568.01M
Revenue (ttm) 127.54M
Net Income (ttm) -4.28M
Shares Out 14.21M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE 47.62
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $39.23
Previous Close $39.83
Change ($) -0.60
Change (%) -1.51%
Day's Open 39.96
Day's Range 38.62 - 40.14
Day's Volume 71,685
52-Week Range 22.38 - 45.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Just like selecting good and undervalued stocks on a regular basis can make you rich, identifying and proactively getting rid of toxic stocks is also crucial to maximizing portfolio returns.

Other stocks mentioned: LAUR, NUAN, VREX
Zacks Investment Research - 1 month ago

Anika Therapeutics (ANIK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Seeking Alpha - 2 months ago

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 2 months ago

Anika (ANIK) delivered earnings and revenue surprises of -462.50% and -1.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

Revenue Increased 7% Year-over-Year to $ 31.7 Million Repaid $25 M illion of Outstanding Credit Facility Continued Expansion of Joint Preservation Product Portfolio

Zacks Investment Research - 2 months ago

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

BEDFORD, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early interv...

GlobeNewsWire - 3 months ago

System designed to alleviate pain and restore function and mobility of the wrist joint System designed to alleviate pain and restore function and mobility of the wrist joint

Zacks Investment Research - 3 months ago

ANIK vs. ILMN: Which Stock Is the Better Value Option?

Other stocks mentioned: ILMN
GlobeNewsWire - 4 months ago

Board Chair Joseph Bower, D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting Jeffery Thompson succeeds Dr. Bower as Chair of the Board

Zacks Investment Research - 4 months ago

ANIK vs. NEO: Which Stock Is the Better Value Option?

Other stocks mentioned: NEO
GlobeNewsWire - 4 months ago

BEDFORD, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with pro...

Zacks Investment Research - 5 months ago

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: ALKS
GlobeNewsWire - 5 months ago

Seasoned financial executive brings broad medical device industry experience and track record of value creation Seasoned financial executive brings broad medical device industry experience and...

Zacks Investment Research - 5 months ago

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: ALKS
Seeking Alpha - 5 months ago

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha - 5 months ago

Anika Therapeutics: After A Stormy Period, Orthopedic Specialist Looks Set Fair

Zacks Investment Research - 5 months ago

Anika (ANIK) delivered earnings and revenue surprises of 142.86% and 83.37%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and...

Zacks Investment Research - 5 months ago

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

Innovative Products Designed to Meet Needs of Surgeons and their Patients in Joint Preservation and Restoration Procedures Innovative Products Designed to Meet Needs of Surgeons and their Pat...

GlobeNewsWire - 6 months ago

BEDFORD, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with prod...

GlobeNewsWire - 7 months ago

Sylvia Cheung to Step Down in August 2020

Seeking Alpha - 8 months ago

Anika Therapeutics, Inc.'s (ANIK) CEO Cheryl Blanchard on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 8 months ago

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

BEDFORD, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leverag...

The Motley Fool - 11 months ago

A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.

Seeking Alpha - 11 months ago

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Anika (ANIK) delivered earnings and revenue surprises of 4.88% and 7.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 11 months ago

BEDFORD, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since Augu...

GlobeNewsWire - 11 months ago

Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline Transaction Accelerates Ani...

GlobeNewsWire - 11 months ago

BEDFORD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, p...

GlobeNewsWire - 11 months ago

Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline Transaction Accelerates Ani...

Zacks Investment Research - 1 year ago

Biotech Stock Outlook: M&A Activity Retains Growth Streak

Other stocks mentioned: ACAD, ALXN, GILD, INCY, REGN, VRTX
Zacks Investment Research - 1 year ago

Possibility of at least an interim trade deal between the largest trading countries of the world boosted investors' confidence on risky assets like equities.

Other stocks mentioned: BDSI, CROX, PLXS, UFI
Zacks Investment Research - 1 year ago

Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Anika Therapeutics, Inc. (ANIK).

Seeking Alpha - 1 year ago

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Anika (ANIK) delivered earnings and revenue surprises of 56.10% and 9.61%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: CROX, KBH, NTES, TMHC
Zacks Investment Research - 1 year ago

Is (ANIK) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

Anika (ANIK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Benzinga - 1 year ago

Here are four stocks to watch, three of them moving on strong earnings.

Other stocks mentioned: AUDC, OC, OSTK
The Motley Fool - 1 year ago

Better-than-expected Q2 earnings results spurred investors' interest in the small biotech.

The Motley Fool - 1 year ago

Wall Street wasn't nearly as optimistic as it should have been about the biotech's second quarter.

Seeking Alpha - 1 year ago

Anika Therapeutics Inc (ANIK) CEO Joseph Darling on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.

Zacks Investment Research - 1 year ago

Anika Therapeutics, Inc. (ANIK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

About ANIK

Anika Therapeutics, together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteo... [Read more...]

Industry
Biotechnology
IPO Date
Apr 29, 1993
CEO
Joseph Darling
Employees
154
Stock Exchange
NASDAQ
Ticker Symbol
ANIK
Full Company Profile

Financial Performance

In 2019, ANIK's revenue was $114.61 million, an increase of 8.58% compared to the previous year's $105.56 million. Earnings were $27.19 million, an increase of 45.25%.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 32.55% from the latest price.

Price Target
$52.00
(32.55% upside)
Analyst Consensus: Buy